Summary: Researchers have created a powerful live-imaging technique that reveals how immune cells in the retina change their behavior well before the blood vessels show visible damage in diabetic retinopathy. By combining a head-fixation device, custom contact lenses, and a specially chosen objective lens, the team recorded high-resolution, real-time activity of retinal microglia in living diabetic mice.
Their observations show that microglia—the retina’s resident immune cells—become hyperactive early in disease progression, indicating inflammation and immune surveillance increase prior to vascular deterioration. The study also reports that the diabetes drug liraglutide normalizes this overactivity, suggesting new diagnostic markers and therapeutic avenues to help prevent vision loss.
Key Facts:
- Early Warning: Microglial hyperactivity appears before visible vascular damage in diabetic retinopathy, offering an earlier indicator of pathology.
- Innovative Imaging: A custom optical setup enables long-term, high-resolution visualization of living retinal cells and their dynamic behavior.
- Therapeutic Insight: Liraglutide restored microglial activity toward normal levels in diabetic mice, independent of changes in blood glucose, pointing to a direct effect on immune cells.
Source: Kobe University
Context: Diabetic retinopathy is a leading cause of blindness worldwide. While vessel damage in the retina has long been considered the main driver of vision loss, mounting evidence indicates that changes in neurons and immune cells precede and contribute to vascular injury.
“Traditionally, vision loss has been attributed to retinal blood vessel damage, but recent work shows that neuronal dysfunction and immune activation begin earlier,” explains Kobe University neurophysiologist TACHIBANA Yoshihisa. “Microglia continuously survey the retinal environment and trigger inflammation when they detect abnormalities, yet it has been difficult to observe their behavior in living tissue.”
Existing microscopy approaches either require complex corrections to remove optical distortions or fail to produce high-resolution live images with commonly available equipment. To overcome these limitations, Tachibana and colleagues designed a practical system that pairs a head-fixation apparatus with tailored contact lenses and an accessible commercial objective lens. This configuration enables stable, clear imaging of the living retina over extended periods, capturing subtle microglial motions and interactions.
In their report in PNAS, the researchers describe how this method revealed increased motility and surveillance behavior of microglia in diabetic mice long before any retinal tissue damage or vessel abnormalities were apparent. These early immune changes were not detectable in conventional ex vivo or fixed-sample analyses, highlighting the value of in vivo, time-resolved retinal imaging for understanding disease onset and progression.
The team also tested the GLP-1 receptor agonist liraglutide and found it normalized microglial activity in diabetic animals. Interestingly, liraglutide reduced microglial activity in healthy mice as well, and these effects occurred without measurable changes in blood glucose levels. “This pattern suggests liraglutide may act directly on microglia or on signaling pathways that control their activation,” says Tachibana.
These findings carry practical implications for early diagnosis and treatment. Detecting microglial hyperactivity could serve as a non-invasive biomarker for early-stage diabetic retinopathy, enabling interventions before irreversible vascular damage and vision loss occur. Furthermore, the imaging platform is likely applicable to other retinal disorders—such as glaucoma and age-related macular degeneration—where immune responses and neuronal changes play critical roles.
“Blindness from diabetic eye disease remains a major global health problem,” Tachibana adds. “We hope this technology can be adapted for clinical use as a non-invasive diagnostic tool, turning the eye into a window for spotting systemic and neurological disease processes at an earlier, more treatable stage.”
Funding: This research was supported by the Bayer Japan Retina Award, Novartis Japan Co. Ltd., Alcon Japan Ltd., Bayer Yakuhin Ltd., the Japan Agency for Medical Research and Development (grants 24wm0425001, 24zf0127010, 24zf0127012), the Japan Science and Technology Agency (grants JPMJMS239F, JPMJMS2299), the Takeda Science Foundation, the Japan Diabetes Foundation, Novo Nordisk Pharma Ltd., and the Japan Society for the Promotion of Science (grants 15K10865, 18K09409, 21K09698, 24K12805, 21H04812, 24K22086, 22K19732, 24K02339).
This work was carried out in collaboration with researchers from the University of Texas Health Science Center at Houston, the National Institute for Physiological Sciences, and Nagoya University.
Key Questions Answered:
A: While retinal blood vessel damage is a major cause of vision loss, current research shows that early abnormalities in neurons and immune cells—especially microglia—contribute to disease onset and may signal risk before vascular damage appears.
A: They developed a specialized imaging system that combines a head-fixation device, customized contact lenses, and a commercial objective lens to produce stable, high-resolution, long-term observations of the living retina and microglial dynamics.
A: Identifying microglial hyperactivity as an early marker opens new opportunities for early intervention, targeted therapies such as drugs that modulate immune cell behavior, and possibly non-invasive clinical diagnostics to prevent progression to blindness.
About this visual neuroscience and neurotech research news
Author: Daniel Schenz
Source: Kobe University
Contact: Daniel Schenz – Kobe University
Image: The image is credited to Neuroscience News
Original Research: Findings reported in PNAS